-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, WMS5nXGWj4uBn/KF1oyTLBc8JXma63Yf/QnQwzWu3hVZQGyQY2XHErJNgbbgXvXE kzPBi5ctXFa30ofc/iwsNw== 0001021408-02-006112.txt : 20020503 0001021408-02-006112.hdr.sgml : 20020503 ACCESSION NUMBER: 0001021408-02-006112 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20020503 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20020503 FILER: COMPANY DATA: COMPANY CONFORMED NAME: WATSON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000884629 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 953872914 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-13305 FILM NUMBER: 02632586 BUSINESS ADDRESS: STREET 1: 311 BONNIE CIRCLE CITY: CORONA STATE: CA ZIP: 92880 BUSINESS PHONE: 9092701400 MAIL ADDRESS: STREET 1: 311 BONNIE CIRCLE CITY: CORONA STATE: CA ZIP: 92880 8-K 1 d8k.txt FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) Of the Securities And Exchange Act Of 1934 May 3, 2002 Date of Report (Date of earliest event reported) WATSON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 0-20045 95-3872914 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification Number) 311 Bonnie Circle 92880 Corona, California (Zip Code) (Address of principal executive offices) (909) 493-5300 (Registrant's telephone number, including area code) N/A (Former Name or Former Address, if Changed Since Last Report) Item 5. Other Events and Regulation FD Disclosure. On May 3, 2002, the registrant issued a news release announcing that it had reached an agreement with the U.S. Food and Drug Administration ("FDA") as to certain regulatory matters related to a manufacturing facility located in Corona, California owned and operated by the registrant's subsidiary, Watson Laboratories, Inc., a Nevada corporation. The terms of the agreement with FDA are contained in the consent decree attached as exhibit 99.2 to this Form 8-K. The consent decree is subject to court approval. The news release and consent decree are attached as exhibits 99.1 and 99.2 to this Form 8-K and are incorporated herein by reference. Statements contained in the attached news release that refer to future events or other non-historical facts are forward-looking statements that reflect the registrant's current perspective of existing trends and information as of the date of the release. Except as expressly required by law, the registrant disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from the registrant's current expectations depending upon a number of factors, including but not limited to uncertainties related to the impact of the consent decree on registrant's business and the ability of registrant to assure FDA of the quality and reliability of its quality and manufacturing systems and controls at its Corona facility and to comply successfully with FDA and other governmental regulations. Readers of the attached news release should understand that failure to comply successfully with FDA regulations could result in sanctions, such as, among others, product recalls or seizures, fines, total or partial suspension of production and/or distribution, suspension of the FDA's review of product applications, injunctions, and civil or criminal prosecution. Certain of these sanctions are available to FDA for violation of the Corona consent decree and the registrant is obligated to immediately comply with any such final order of FDA, pending any court review, unless a court instructs otherwise. In addition, forward-looking statements may be adversely affected by other risks and uncertainties as detailed in registrant's periodic public filings with the Securities and Exchange Commission, including but not limited to registrant's Annual Report on Form 10-K for the year ended December 31, 2001. Item 7. Financial Statements, Pro Forma Financial Information and Exhibits. Exhibits. -------- 99.1 News Release titled "Watson Pharmaceuticals Reaches Agreement with FDA on Terms of Corona, California Consent Decree" dated May 3, 2002. 99.2 Consent Decree of Permanent Injunction as filed with the United States District Court for the Central District of California. 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 3, 2002. WATSON PHARMACEUTICALS, INC. By: /s/ Robert C. Funsten -------------------------------------- Robert C. Funsten Senior Vice President, General Counsel and Secretary 3 EX-99.1 3 dex991.txt NEWS RELEASE EXHIBIT 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE - --------------------- CONTACTS: Watson Pharmaceuticals, Inc. Patty Eisenhaur Director, Investor Relations (909) 493-5611 WATSON PHARMACEUTICALS REACHES AGREEMENT WITH FDA ON TERMS OF CORONA, CALIFORNIA CONSENT DECREE -- As Expected, the Decree Requires No Fine, Shutdown, Product Recalls or Reduction in Production or Service -- CORONA, Calif., May 3, 2002 - Watson Pharmaceuticals, Inc. (NYSE: WPI) announced today that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on the terms of a consent decree with respect to Watson's Corona, California manufacturing facility. As expected, the final agreement with FDA does not require any fine, a facility shutdown, product recalls or any reduction in production or service at the Corona facility. The decree is subject to court approval. The consent decree applies only to Watson's Corona facility and not its other six manufacturing sites. Watson manufactures 26 of its 170 branded and generic products at its Corona facility and currently is the sole supplier of several of these products. The decree requires Watson to ensure that its Corona, California facility complies with FDA's current Good Manufacturing Practices (cGMPs) regulations. Pursuant to the agreement, Watson will hire an independent expert to conduct inspections of the Corona facility at least once each year. A report of each inspection by the independent expert will be prepared and submitted to the FDA and Watson, with an opinion from the expert as to cGMP compliance at the Corona facility. The first such expert report will be due in the first quarter of 2003. "By entering into this agreement with FDA, we affirm our confidence in the quality of our products and our commitment to continuing our quality initiatives," said Allen Chao, Watson's Chairman and Chief Executive Officer. "We worked closely and cooperatively with the FDA in reaching this agreement and look forward to a constructive relationship with them in the future." Statements contained in this news release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors, including but not limited to uncertainties related to the impact of the consent decree on Watson's business and the ability of Watson to assure FDA of the quality and reliability of its quality and manufacturing systems and controls at its Corona facility and to comply successfully with FDA and other governmental regulations. The reader of this news release should understand that failure to comply successfully with FDA regulations could result in sanctions, such as, among others, product recalls or seizures, fines, total or partial suspension of production and/or distribution, suspension of the FDA's review of product applications, injunctions, and civil or criminal prosecution. Certain of these sanctions are available to FDA for violation of the Corona consent decree and the Company is obligated to immediately comply with any such final order of FDA, pending any court review, unless a court instructs otherwise. In addition, forward-looking statements may be adversely affected by other risks and uncertainties as detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2001. This news release of Watson Pharmaceuticals, Inc. is available at Watson's Web site at www.watsonpharm.com. In addition, this news release is available through PR Newswire's Web site at www.prnewswire.com. Watson Pharmaceuticals, Inc., headquartered in Corona, California, is a leading specialty pharmaceutical company that develops, manufactures, markets and distributes branded and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses. # # # EX-99.2 4 dex992.txt CONSENT DECREE Exhibit 99.2 ROBERT D. MCCALLUM, JR. Assistant Attorney General Civil Division JOHN S. GORDON United States Attorney ROGER E. WEST (Bar No. 58609) Assistant United States Attorney First Assistant Chief, Civil Division Suite 7516, Federal Building 300 North Los Angeles Street Los Angeles, California 90012 Telephone: (213) 894-2461 GERALD C. KELL Senior Trial Counsel Office of Consumer Litigation U.S. Department of Justice P.O. Box 386 Washington, D.C. 20044 (202) 514-1586 Attorneys for Plaintiff EUGENE M. PFEIFER MARK S. BROWN ELAINE TSENG (Bar No. 206433) King & Spalding 1730 Pennsylvania Ave. NW Washington, D.C. 20006-4706 (202) 737-0500 Attorneys for Defendants UNITED STATES DISTRICT COURT FOR THE CENTRAL DISTRICT OF CALIFORNIA - ------------------------------------- ) UNITED STATES OF AMERICA, ) ) Plaintiff, ) ) CV-02-___________ v. ) ) CONSENT DECREE OF WATSON LABORATORIES, INC., a ) PERMANENT INJUNCTION corporation, and ) ) ALLEN Y. CHAO, an individual. ) ) Defendants. ) ) - ------------------------------------- Plaintiff, United States of America, having commenced this action by filing its Complaint for Injunction on behalf of the United States Food and Drug Administration (FDA) on the _____day of _______, 2002, and defendants Watson Laboratories, Inc. ("Watson"), a Nevada corporation, and Allen Y. Chao, an individual (collectively, "defendants"), denying the allegations in the Complaint and disclaiming any liability in connection therewith, having appeared and having consented to the entry of this Decree without contest and before any testimony has been taken, and the United States of America having consented to this Decree: THEREFORE, IT IS ORDERED, ADJUDGED, AND DECREED that: I. This Court has jurisdiction over the subject matter and over all parties to this action. II. The Complaint for Injunction states a claim for relief against defendants under the FD&C Act. III. Upon entry of this Decree, Defendants and each and all of their officers, directors, agents, employees, representatives, attorneys, successors, assigns and those persons in active concert or participation with any of them who have received actual notice of this Decree, shall be permanently enjoined pursuant to 21 U.S.C. ss. 332(a) and the inherent equity powers of this Court from directly or indirectly doing or causing: (a) the introduction or delivery for introduction into commerce of any article of drug, 21 U.S.C. ss. 321(g), that has been manufactured, processed, packed, or held by defendants at Watson's Corona, California facility ("Corona facility") in a manner that causes it to be adulterated within the meaning of 21 U.S.C. 2 ss.351(a)(2)(B); and (b) manufacturing, processing, packing, or holding any drug at the Corona facility, which drug or any of its components is being held for sale after shipment in interstate commerce, in a manner that causes it to be adulterated within the meaning of 21 U.S.C. ss. 351(a)(2)(B). IV. Within forty-five (45) days after entry of this Decree, defendants shall, at Watson's expense, retain one or more person(s) who by reason of education, training and experience is (are) qualified to inspect a drug manufacturing facility, conduct investigations, design appropriate procedures, controls, and standard operating procedures (SOPs), and prepare reports (hereafter, the "expert"), as set forth in this Decree, evaluating whether defendants' methods, facilities, and controls used at the Corona facility for manufacturing, processing, packing, holding, and distributing drugs are in compliance with 21 U.S.C. ss. 351(a)(2)(B) and applicable regulations of 21 C.F.R. Parts 210-211 relating to the safety, identity, strength, quality, and purity, of drug products. V. Within 225 days from retaining the expert specified in paragraph IV, and at a frequency no less than yearly intervals thereafter, the expert shall inspect the methods, facilities, and controls at the Corona facility to determine whether the defendants are in compliance with 21 U.S.C. ss. 351(a)(2)(B) and 21 C.F.R. Parts 210-211. The expert shall prepare reports of these inspections expressing in detail an opinion whether the defendants are or are not in compliance, and shall submit these reports concurrently to FDA and defendants no later than fifteen (15) 3 business days after the date the inspections referred to in this paragraph are completed. If the expert determines that any of defendants' information or data (whether orally or in writing, including, but not limited to raw data, analytical data, reports, memoranda, and investigations) is inaccurate, false, incomplete, or missing (hereinafter "irregularities"), and such data irregularities have not already been reported to FDA by the defendants, then the expert must report immediately and concurrently to FDA and the defendants the discovery of such irregularities. The foregoing sentence shall not be construed to require the expert to evaluate the integrity of data or other information contained or referenced in any of the defendants' pending or approved drug applications. If inspections conducted pursuant to this paragraph show that defendants are not in compliance with 21 U.S.C. ss. 351(a)(2)(B) and 21 C.F.R. Parts 210-211, then reports prepared pursuant to this paragraph shall specify each corrective action that defendants need to implement to achieve compliance and the estimated time for completion of each such action. The expert's inspections and reports required by the above paragraph shall encompass, but not be limited to, the following: 1. Defendants' quality assurance and quality control program, current organizational structure, the specific responsibilities of each Watson work unit that is involved in manufacturing drugs, and the management controls Watson places thereon; 2. Defendants' systems and procedures for the handling of customer complaints concerning Watson drug products; 4 3. Defendants' validation of analytical methods, qualification of manufacturing equipment, and cleaning validation; 4. Defendants' systems and procedures for stability testing; 5. Defendants' maintenance and tracking of laboratory, computer, and production data; 6. Defendants' procedures for the validation of computer software programs that are part of an automated production or quality assurance system; and 7. Defendants' systems and procedures for training of employees. VI. If at any time after this Decree has been entered, FDA determines, based on the results of an inspection or the analyses of samples, a report or data prepared or submitted by defendants or the expert pursuant to this Decree, or any other information, that with respect to the Corona facility, defendants have failed to comply with any provision of this Decree, or have violated the FD&C Act or regulations promulgated thereunder; or that additional corrective actions are necessary to achieve compliance with the FD&C Act or regulations promulgated thereunder, or to protect the public health, the Director of the Los Angeles District Office, FDA, after consultation with the Director of the Office of Compliance, Center for Drug Evaluation and Research, FDA, may, as and when it deems necessary, order defendants in writing to take appropriate action, including but not limited to, ordering that defendants immediately take one or more of the following actions with respect to the Corona facility: 5 A. revise, modify, or expand any report(s) or plan(s) prepared pursuant to this Decree; B. submit additional reports or information to FDA; C. cease manufacturing, processing, packing, holding, and/or distributing drugs at the Corona facility; D. recall specified drug products released from the Corona facility in accordance with procedures identified by FDA; or E. take any other corrective action(s) as FDA, in its discretion, deems necessary to protect the public health or bring defendants and their drugs at the Corona facility into compliance with the FD&C Act or the regulations promulgated thereunder. Any such order issued pursuant to this paragraph shall specify the alleged violations and fully describe the factual bases for the alleged violations. Within ten (10) business days after receiving such order from FDA, defendants shall respond and advise FDA in writing that: (1) defendants are undertaking or have undertaken the action(s), in which event defendants also shall describe the specific action(s) taken or proposed to be taken and a proposed schedule for completing the action; or (2) defendants disagree with the request. If defendants notify FDA that they do not agree with FDA's order, defendants shall fully explain in writing the basis for their disagreement; in so doing, defendants also may propose specific alternative actions and specific time frames for achieving FDA's objectives. After receiving defendants' response, FDA shall provide the defendants with written notice either affirming, withdrawing, or modifying the order, which shall constitute final agency action. If 6 FDA affirms or modifies its order, the defendants shall, upon receipt of FDA's order, immediately implement the order (as modified, if applicable). If the defendants so choose, they may seek judicial review of the order, which review shall be pursuant to the standards set forth in (P). XII of this Decree. However, neither the filing nor pendency of such review shall relieve defendants of their obligations to comply immediately and fully with the order, unless the court instructs otherwise. VII. All reports specified in this Decree to be sent to FDA shall be prominently marked "Decree Correspondence" and shall be sent to the Director, Los Angeles District Office, HFR-PA200, FDA, 19900 MacArthur Boulevard, Suite 300, Irvine, CA 92612-2445. VIII. Representatives of FDA shall be permitted, without prior notice and as and when FDA deems necessary, to take any measures necessary to monitor and ensure continuing compliance with the terms of this Decree, including but not limited to, making inspection of the Corona facility and all drugs and equipment therein, finished and unfinished materials, containers, labeling, records (including, but not limited to, all computer hardware and software, computer printouts, raw data and laboratory data), files, papers, SOPs, and processes and controls; taking photographs and video recordings; collecting samples of any drugs; and copying any of the foregoing records. The costs of all such inspections, record reviews, other measures, and sample analyses shall be borne by defendant Watson at the rates specified below in paragraph X. The authority described in this paragraph shall be separate and apart from, and in addition to, statutory authority to make inspections under the FD&C Act. 7 IX. Defendant Watson shall reimburse FDA for the costs of all FDA inspections, examinations, analyses, and reviews that FDA deems necessary to evaluate defendants' compliance with any part of this Decree at the standard rates prevailing at the time the activities are accomplished. As of the date that this Decree is signed by the parties, these rates are: $65.14 per hour and fraction thereof per representative for inspection work, $78.07 per hour or fraction thereof per representative for analytical or review work, 34.5 cents per mile for travel expenses by automobile, government rate or the equivalent for travel by air, and the published government per diem rate or the equivalent for the areas in which the inspections are performed per day per representative for subsistence expenses, where necessary. In the event that the standard rates applicable to FDA supervision of court-ordered compliance are modified, these rates shall be increased or decreased without further order of the Court. X. Within ten (10) calendar days after entry of this Decree, defendant Watson shall provide a copy of this Decree to its officers, directors, attorneys, and all employees in a supervisory or managerial capacity. Within thirty (30) calendar days after entry of this Decree, defendant Watson shall ensure that all other employees involved in the manufacture, storage, or distribution of drugs at its Corona facility are aware of the terms of this Decree, whether by providing them with copies or by posting copies in conspicuous places frequented by and readily available to employees. Defendant Watson also shall, within forty-five (45) calendar days after 8 entry of this Decree, provide FDA with an affidavit stating the fact and manner of compliance with this paragraph and identifying the names and positions of all persons involved in the manufacture, storage, or distribution of drugs provided with a copy of this Decree or other manner in which the Decree was made available to such persons. XI. Defendant Watson shall notify FDA in writing within 24 hours of any suspension(s) of operations and at least fifteen (15) calendar days before any reorganization, dissolution, or assignment or sale resulting in the emergence of a successor corporation, the creation or dissolution of subsidiaries, or any other change of the corporate structure or function of Watson. Defendant Watson shall serve a copy of this Decree on any prospective purchaser or assignee at least fifteen (15) calendar days prior to the assignment or change in ownership. Defendant Watson shall furnish FDA with an affidavit of compliance with this paragraph no later than ten (10) calendar days prior to such assignment or change in ownership. XII. All decisions conferred upon FDA in this Decree shall be vested in the discretion of FDA. FDA decisions or Orders made or issued pursuant to this Decree shall be transmitted to defendants in writing. If challenged by defendants, any FDA decision or Order made or issued pursuant to this Decree shall be reviewed by this Court under the arbitrary and capricious standard set forth in 5 U.S.C. ss. 706(2)(A). Such review shall be based exclusively on the record before FDA at the time the decision or Order in dispute was made or issued, and no discovery may be taken by either party. 9 XIII. Defendants' obligations under this Decree do not modify or absolve Defendants from any obligation to comply with the FD&C Act or any other federal statute or regulation. XIV. This Court shall retain jurisdiction over this action and the parties hereto for the purpose of enforcing and modifying this Decree and for the purpose of granting such additional relief as may be necessary and appropriate. If defendants violate this Decree and are found in civil or criminal contempt thereof, Defendants shall, in addition to other remedies, reimburse the United States for its attorney's fees, investigational expenses, and court costs relating to such contempt proceedings. Dated this ________ day of _______________, 2002. -------------------------------- UNITED STATES DISTRICT JUDGE 10 We hereby consent to the entry of the foregoing Decree and to its form and contents. ROBERT D. MCCALLUM, JR. Assistant Attorney General Civil Division U.S. Department of Justice /s/ ALLEN Y. CHAO - --------------------------------- JOHN S. GORDON ALLEN Y. CHAO, President, United States Attorney for defendant WATSON LABORATORIES, INC. ROGER E. WEST (Bar No. 58609 Assistant United States Attorney /s/ ALLEN Y. CHAO /s/ GERALD C. KELL - ---------------------------------- -------------------------------- ALLEN Y. CHAO, GERALD C. KELL an individual Senior Trial Attorney Office of Consumer Litigation /s/ EUGENE M. PFEIFER Civil Division - --------------------------------- U.S. Department of Justice EUGENE M. PFEIFER P.O. Box 386 Attorney for Individual Washington, D.C. 20044 Defendant (202) 514-1586 King & Spalding 1730 Pennsylvania Ave. NW Washington, D.C. 20006-4706 OF COUNSEL: (202)737-0500 DANIEL E. TROY Chief Counsel KEVIN M. FAIN /s/ MARK S. BROWN Associate Chief Counsel - --------------------------------- for Enforcement EUGENE M. PFEIFER, ESQ. MARK S. BROWN Food and Drug Administration ELAINE TSENG (Bar No. 206433) 5600 Fishers Lane Attorneys for Corporate Rockville, Maryland 20857 Defendant King & Spalding 1730 Pennsylvania Ave. NW Washington, D.C. 20006-4706 (202)737-0500 11 -----END PRIVACY-ENHANCED MESSAGE-----